Generic Savaysa Availability
Last updated on Jan 8, 2025.
Savaysa is a brand name of edoxaban, approved by the FDA in the following formulation(s):
SAVAYSA (edoxaban tosylate - tablet;oral)
-
Manufacturer: DAIICHI SANKYO INC
Approval date: January 8, 2015
Strength(s): EQ 15MG BASE [RLD], EQ 30MG BASE [RLD], EQ 60MG BASE [RLD]
Has a generic version of Savaysa been approved?
No. There is currently no therapeutically equivalent version of Savaysa available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Savaysa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,365,205
Patent expiration dates:
- April 18, 2027✓
- April 18, 2027
-
Pharmaceutical composition
Patent 9,149,532
Issued: October 6, 2015
Inventor(s): Kojima Masazumi & Kuno Yoshio & Nakagami Hiroaki & Sagasaki Shinji & Ishidoh Koichi & Sekiguchi Gaku
Assignee(s): Daiichi Sanykyo Company, LimitedTo provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range.
Patent expiration dates:
- March 28, 2028✓
- March 28, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 18, 2026 - ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
More about Savaysa (edoxaban)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: factor Xa inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
